Cellestetix

Cellestetix is a disruptive biotechnology company specializing in the research, development, and commercialization of plant-based exosome formulations. Founded by genetic engineers Dr. Polen Koçak and Dr. Merve Yıldırım, the company leverages over a decade of experience in biotechnology and gene therapy to create high-performance solutions for the regenerative beauty and wellness markets.

Key Capabilities

• Plant-Based Exosome Technology: Cellestetix utilizes a proprietary biomimetic exosome technology that creates "coded" molecules designed to signal cells with precise information. Unlike traditional animal-derived alternatives, their technology is 100% vegan, cruelty-free, and highly stable.

• Targeted Precision: The platform’s proprietary isolation process allows for the creation of optimized and targeted exosomes that treat skin, hair, and overall wellness at a molecular level, offering a new frontier in regenerative biology.

• SickScience Labs: Under its consumer-facing brand, SickScience, the company has successfully launched clinically tested products in the U.S. market, gaining significant recognition from major media outlets like Forbes and WWD for their breakthrough in molecular-level hair and skin care.

• Scalable R&D: While the core exosome research and development are conducted in specialized laboratories in Turkey, the company manages final production and marketing from its facilities in the U.S., positioning itself as a global player in the biotech-cosmetic industry.

Strategic Value

Cellestetix represents a significant shift from traditional topical treatments to precision cell signaling. By applying advanced medical research—originally intended for cancer and wound care—to the consumer beauty and longevity sectors, they provide a science-backed alternative to luxury skincare. With $2 million in seed funding and a leadership team comprising former Estee Lauder executives, Cellestetix is poised to lead the rapidly growing regenerative beauty market.